Recursion Pharmaceuticals, Inc. RXRX Business Segments — Clinical development

Similar metrics at other companies

BCAXReportable Segment — Clinical operations and development

$23.21M+24.4%

NVCTClinical Development — Number Of Reportable Segments

10.0%

INBXReportable Segment — Clinical trials

$8.83M-25.9%

AVTXReportable Segment — Clinical expenses

$3.71M-48.6%

VIRReportable Segment — Clinical costs

$22.53M+10.7%

INBXReportable Segment — Research And Development Expense, Clinical Trials

$9.18M-30.8%

FAQ

What is Recursion Pharmaceuticals, Inc.'s business segments — clinical development?

Recursion Pharmaceuticals, Inc. (RXRX) reported business segments — clinical development of $10.67M in Q2 2026.

How has Recursion Pharmaceuticals, Inc.'s business segments — clinical development changed year-over-year?

Recursion Pharmaceuticals, Inc.'s business segments — clinical development decreased by 10.8% year-over-year, from $11.96M to $10.67M.

What is the long-term trend for Recursion Pharmaceuticals, Inc.'s business segments — clinical development?

Over 3 years (2022 to 2025), Recursion Pharmaceuticals, Inc.'s business segments — clinical development has grown at a 12.1% compound annual growth rate (CAGR), from $32.93M to $46.38M.

What does business segments — clinical development mean?

Tracks the costs incurred for advancing product candidates through clinical trials and regulatory approval processes. This is a key indicator of the progress and financial burden associated with moving assets from the laboratory to potential commercialization.